Abstract A003: Baseline Systolic Blood Pressure Modifies the Net Benefit of Combination Antithrombotic Therapy After Ischemic Stroke/TIA in Patients With NVAF and ASCVD: Subanalysis of the ATIS–NVAF trial

Stroke 2026

View at publisher
Authors: Hajime Ikenouchi, Takuya Saito, Yukako Yazawa, Shuhei Okazaki, Kanta Tanaka, Ryosuke Doijiri, Masatoshi Koga, Masafumi Ihara, Shiro Yamamoto, Koko Asakura, Haruko Yamamoto, Ḱazunori Toyoda
+1 more Hiroshi Yamagami
DOI: 10.1161/str.57.suppl_1.a003
Cited by: 0

Abstract

Background: The optimal antithrombotic strategy after ischemic stroke or TIA in patients with nonvalvular atrial fibrillation (NVAF) and atherosclerotic cardiovascular disease (ASCVD) remains uncertain. We tested whether baseline systolic blood pressure (SBP) modifies the net clinical effect of intensified therapy. Methods: The ATIS–NVAF trial randomized patients with ischemic stroke/TIA, NVAF, and ASCVD to oral anticoagulant (OAC) monotherapy or OAC plus single antiplatelet therapy. In this subanalysis of participants with baseline SBP data, patients were stratified by SBP

Fields of Study & Subjects

Atrial Fibrillation Management and Outcomes Acute Ischemic Stroke Management Antiplatelet Therapy and Cardiovascular Diseases

Publication details

Journal / source
Stroke
Volume
57
Issue
Suppl_1
Publication date
29 January 2026
Language
EN